Related Experiment Videos
[Biology and gene therapy of glioma]
1Clinique neurologique, Hôpital de La Salpêtrière, Paris.
Abstract:
Although prognosis of malignant gliomas did not change dramatically for the last 15 years, tumorigenesis is much better understood. The study of the genetic alterations occurring in these tumors allowed to recognise the most critical genes involved, which are either overexpressed oncogene, or inactivated tumor suppressor gene. Gene therapy is a natural outcome of such progresses. One way of tumor gene therapy is based on correction of genetic defect either by introducing the missing tumor suppressor gene or by blocking overexpression of an activated oncogene. Alternatively, "destructive" gene therapy is based on a "suicide" gene introduced in tumor cells. These approach results now in phase 1 protocol.
Insights
Gene therapy offers new hope for malignant gliomas by targeting genetic defects. Researchers are exploring introducing tumor suppressor genes or using "suicide" genes for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Malignant gliomas have a poor prognosis despite advances in understanding tumor development.
- Genetic alterations, including oncogene overexpression and tumor suppressor gene inactivation, are key to glioma tumorigenesis.
Purpose:
- To explore gene therapy strategies for malignant gliomas based on current understanding of their genetic basis.
- To introduce novel therapeutic approaches targeting specific genetic defects in glioma cells.
Summary:
- Gene therapy for malignant gliomas involves correcting genetic defects by introducing tumor suppressor genes or inhibiting oncogenes.
- An alternative strategy employs "suicide" genes to induce cell death in tumor cells.
- These gene therapy approaches are progressing to Phase 1 clinical trials.
Impact:
- Advances in understanding glioma genetics pave the way for targeted gene therapies.
- Gene therapy offers a promising new avenue for treating malignant gliomas, potentially improving patient outcomes.
- Early-phase clinical trials will evaluate the safety and efficacy of these novel genetic treatments.